Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study

Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study

The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune respons...

Full description

Bibliographic Details
Main Authors: Eleni Papadokostaki, Anastasios Tentolouris, Ioanna A. Anastasiou, Mina Psichogiou, Evangelia Iliaki, Ioanna Eleftheriadou, Angelos Hatzakis, Nikolaos Tentolouris
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Vaccines
Subjects:
humoral immune response
SARS-CoV-2
COVID-19
vaccine
antibodies
Online Access:https://www.mdpi.com/2076-393X/10/3/382

Similar Items

Similar Items